Patents by Inventor Pingkun Zhou

Pingkun Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230250489
    Abstract: The present disclosure relates to a biomarker, a kit, and a method for detection or auxiliary detection of proton irradiation and use thereof, and belongs to the field of biotechnology. The present disclosure provides a microbial biomarker for detection or auxiliary detection of proton irradiation, in which the microbiota includes at least one of Cyanobacteria, Epsilonbacteraeota, Anaerovorax and Helicobacter. In the present disclosure, whether a subject to be tested is exposed to proton radiation is accurately determined by detection of an abundance or relative abundance of DNA of the microbial biomarker. This is conductive to timely accident rescue, casualty treatment and clinical treatment application, which is of great significance to radiation treatment.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 10, 2023
    Applicant: Academy of Military Medical Sciences
    Inventors: Hua GUAN, Shanshan Gao, Pingkun Zhou, Chenjun Bai, Yuchen Li, Hongling Zhao, Wen Zhang, Xiaochang Liu
  • Patent number: 7981939
    Abstract: Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2) significant therapeutic effect, with remarkable proliferation inhibiting and pro-apoptotic effects in tumor cells; (3) a broad-spectrum anticancer activity; (4) suitable to be used in combination with antimetabolites, to enhance the effects and meanwhile lower the toxicity, and also to reduce multi-drug resistance; (5) convenient and safe administration, the main route being oral.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: July 19, 2011
    Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
    Inventors: Pingkun Zhou, Yuqian Yan, Lin Wang, Jianli Sui
  • Publication number: 20110098362
    Abstract: Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2) significant therapeutic effect, with remarkable proliferation inhibiting and pro-apoptotic effects in tumor cells; (3) a broad-spectrum anticancer activity; (4) suitable to be used in combination with antimetabolites, to enhance the effects and meanwhile lower the toxicity, and also to reduce multi-drug resistance; (5) convenient and safe administration, the main route being oral.
    Type: Application
    Filed: February 25, 2008
    Publication date: April 28, 2011
    Inventors: Pingkun Zhou, Yuqian Yan, Lin Wang, Jianli Sui
  • Publication number: 20080221221
    Abstract: Use of 2-bromo-isovanillin in the preparation of an anticancer medicament and/or radio- and chemotherapy sensitizing medicament is disclosed. The medicament for the treatment of cancers and/or for radio- and chemotherapy sensitization comprising 2-bromo-isovanillin as active ingredient provided herein has the following features: (1) low toxicity, without evident adverse effects; (2) significant therapeutic effect, with remarkable proliferation inhibiting and pro-apoptotic effects in tumor cells; (3) a broad-spectrum anticancer activity; (4) suitable to be used in combination with antimetabolites, to enhance the effects and meanwhile lower the toxicity, and also to reduce multi-drug resistance; (5) convenient and safe administration, the main route being oral.
    Type: Application
    Filed: February 25, 2008
    Publication date: September 11, 2008
    Inventors: Pingkun Zhou, Yuqian Yan, Lin Wang, Jianli Sui